Skip to main content
Oculis Holding AG logo

Oculis Holding AG — Investor Relations & Filings

Ticker · OCS ISIN · CH1242303498 LEI · 5067005370C2KK324336 IC Manufacturing
Open in API
Filings indexed 321 across all filing types
Latest filing 2025-04-25 Share Issue/Capital Cha…
Country CH Switzerland
Listing IC OCS

About Oculis Holding AG

https://www.oculis.com/

Oculis Holding AG is a global, clinical-stage biopharmaceutical company focused on developing innovative therapies for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs. The company's pipeline aims to transform current treatment paradigms. Key candidates include OCS-01, a topical eye drop using the proprietary OPTIREACH® technology, investigated as a potential first non-invasive treatment for Diabetic Macular Edema (DME). Another lead asset is Privosegtor, a novel peptoid small molecule being developed as a neuroprotective therapy for optic neuropathies such as Acute Optic Neuritis. The pipeline also features Licaminlimab, an anti-TNFα eye drop candidate for treating Dry Eye Disease.

Recent filings

Filing Released Lang Actions
Oculis Updates Share Capital
Share Issue/Capital Change Classification · 99% confidence The document explicitly discusses an update to the company's share capital, detailing the issuance of new registered ordinary shares due to the exercise of equity awards and warrants. It states the total number of registered shares has increased and this change has been registered with the Commercial Register. This directly relates to changes in the company's capital structure, matching the definition for 'Share Issue/Capital Change' (SHA). The document length is short, but the content is a direct announcement of a capital change, not just an announcement that a report is available.
2025-04-25 English
6-K
Regulatory Filings
2025-04-15 English
Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets
Regulatory Filings Classification · 95% confidence The document is a press release announcing an upcoming R&D Day event where the company will present updates on its clinical pipeline and strategy. It provides details on the event's purpose, location, and registration, and mentions that presentation materials will be available on the company's website after the event. Since this is an announcement of an investor-focused presentation rather than the presentation itself, and it does not fit into specific categories like earnings releases or regulatory filings, it is classified as a Report Publication Announcement (RPA) regarding the upcoming investor materials.
2025-04-15 English
Oculis Hosts R&D Event Today to Sho..
Regulatory Filings Classification · 99% confidence The document is a press release announcing that Oculis Holding AG will host an R&D Event on April 15, 2025, detailing updates on its pipeline assets (OCS-01, OCS-02, OCS-05), clinical trial timelines (DIAMOND trials, Phase 2/3 for OCS-02), and future development plans. It also mentions a subsequent investor meeting in Iceland. Crucially, the text states: 'A copy of the presentation will be available following the meeting by visiting the Oculis website on the Events and Presentations section under Investors & Media.' This indicates the document itself is an announcement about an upcoming event and the availability of related materials, rather than the full financial report (10-K, IR) or the presentation itself (IP). Since it is an announcement regarding the publication/availability of materials related to company events/updates, it fits best under Report Publication Announcement (RPA) or potentially Regulatory Filing (RNS) if RPA wasn't available. Given the context of announcing an R&D Day and the subsequent availability of the presentation, RPA is the most precise fit, as it signals the publication of investor-facing materials.
2025-04-15 English
Oculis lýkur innritun sjúklinga í báðar DIAMOND fasa 3 rannsóknirnar á OCS-01 sem meðferð við sjónhimnubjúg af völdum sykursýki
Regulatory Filings Classification · 95% confidence The document is a press release issued by Oculis Holding AG announcing the completion of patient enrollment for their DIAMOND Phase 3 clinical trials. It provides details on the trial progress, expected timelines for topline data, and mentions an upcoming R&D Day. This is a standard corporate announcement regarding operational milestones and clinical trial progress, which falls under the category of general regulatory announcements/filings.
2025-04-10 Icelandic
Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema
Regulatory Filings Classification · 95% confidence The document is a press release from Oculis Holding AG announcing the completion of patient enrollment for its Phase 3 DIAMOND clinical trials. It provides details on the trial progress, expected data readout, and future R&D event information. It does not constitute a full financial report, audit, or regulatory filing, but rather an announcement of company operational progress. Under the provided definitions, this fits best as a general regulatory announcement or corporate update, which falls under the RNS category.
2025-04-10 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.